Gregory Landers
Impact in
- Otorhinolaryngology top 0.5%
- Head and Neck Cancer Studies
- Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
Papers in
-
- Head and Neck Cancer Studies 1
- Oncology 2
- Cancer Immunotherapy and Biomarkers 2
- Pancreatic and Hepatic Oncology Research 1
- Journals
- The Lancet (3 papers)Nature Medicine (1 paper)JAMA Oncology (1 paper)The Lancet Oncology (1 paper)
- Partner nations
- United States
In The Last Decade
Gregory Landers
6 papers receiving 6.9k citations
Gregory Landers's Hit Papers
Peers
Comparison fields: 5 of 90
- Otorhinolaryngology 856
- Oncology 3.9k
- Pulmonary and Respiratory Medicine 2.1k
- Gastroenterology 266
- Immunology 789
Countries citing papers authored by Gregory Landers
This map shows the geographic impact of Gregory Landers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregory Landers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregory Landers more than expected).
Fields of papers citing papers by Gregory Landers
This network shows the impact of papers produced by Gregory Landers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregory Landers. The network helps show where Gregory Landers may publish in the future.
No co-authors to show.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial Hit paper breakdown → | 2019 | 2691 |
| 2 | Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study Hit paper breakdown → | 2019 | 2460 |
| 3 | Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial Hit paper breakdown → | 2018 | 1056 |
| 4 | Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial Hit paper breakdown → | 2023 | 435 |
| 5 | Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability–High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials Hit paper breakdown → | 2021 | 331 |
| 6 | 2023 | 40 |
About Gregory Landers
Gregory Landers is a scholar working on Otorhinolaryngology, Oncology, Pulmonary and Respiratory Medicine, Insect Science and Renewable Energy, Sustainability and the Environment, having authored 6 papers that have together received 7.0k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (2 papers), Lung Cancer Treatments and Mutations (1 paper), Head and Neck Cancer Studies (1 paper) and Pancreatic and Hepatic Oncology Research (1 paper). The work is most often cited by research in Otorhinolaryngology (856 citations), Oncology (3.9k citations), Pulmonary and Respiratory Medicine (2.1k citations), Gastroenterology (266 citations) and Immunology (789 citations). Gregory Landers has collaborated with scholars based in United States. Their work appears in journals such as The Lancet, Nature Medicine, JAMA Oncology and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.